title: Cardiovascular risk assessment with regadenoson SPECT MPI in patients with end-stage renal disease is safe, effective, and well tolerated: Does it matter?
authors.affiliation: Cardiology Division, Department of Medicine, University of Rochester Medical Center, Box 679, Rochester, NY, USA.
authors.forename: Erica O
authors.initials: EO
authors.lastname: Miller
authors.affiliation: Cardiology Division, Department of Medicine, University of Rochester Medical Center, Box 679, Rochester, NY, USA. ronald_schwartz@urmc.rochester.edu.|Nuclear Medicine Division, Department of Imaging Sciences, University of Rochester Medical Center, Rochester, NY, USA. ronald_schwartz@urmc.rochester.edu.
authors.forename: Ronald G
authors.initials: RG
authors.lastname: Schwartz
mesh_terms: D002318:Cardiovascular Diseases / Q000209:etiology*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000000981:diagnostic imaging*; D055414:Myocardial Perfusion Imaging / Q000009:adverse effects*; D011687:Purines / Q000009:adverse effects*; D011720:Pyrazoles / Q000009:adverse effects*; D051436:Renal Insufficiency, Chronic / Q000150:complications / Q000000981:diagnostic imaging; D018570:Risk Assessment; D015899:Tomography, Emission-Computed, Single-Photon / Q000009:adverse effects*
chemical_list: D011687:Purines; D011720:Pyrazoles; C430916:regadenoson